CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
- Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise
- Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansion
Cambridge, UK: CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech. In response to rapidly growing demand for the Company’s OOC solutions, the agreement establishes a new regional distribution network in Japan, providing customers streamlined access to localized support and technical expertise, and solidifies CN Bio’s presence in this key market.
Global legislative changes and localized drives have influenced the growing demand in Japan for new approach methodologies (NAMs). As a result, the country’s OOC market is expanding rapidly; predicted to reach a value of $28.2M by 2030 (CAGR 30.7%)1. Pharmaceutical and biotech companies are recognizing the potential of these approaches to improve preclinical efficacy and safety data generation in drug discovery and development workflows, leading to reduced failure rates of new drug candidates. CN Bio has strategically partnered with Primetech Corp. to strengthen its presence in the Asia-Pacific region, expanding direct sales and product support for the Company’s range of industry-leading PhysioMimix® OOC Systems and solutions to existing and new customers.
CN Bio’s benchtop PhysioMimix OOC range accurately mimics human physiology in the laboratory. Using advanced in vitro human organ models, these systems enable more accurate predictions of human drug responses to support the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models provide insights into crucial aspects of preclinical drug development, including drug bioavailability, toxicology and disease modelling, providing information on how drugs will perform in patients and reduce the risk of costly late-stage failures in the clinic.
Ryosuke Ogihara, CEO, Primetech Corporation, said: “We are pleased to announce the commencement of our partnership with CN Bio to offer the Company’s range of microphysiological systems and reagents. This innovative technology opens new possibilities in the field of drug discovery and development, and can significantly accelerate the discovery process. Our company is committed to providing cutting-edge solutions to drive our customers’ success, and we are confident that CN Bio’s products and expertise will greatly enhance their research efficiency.”
“Partnering with an established distributor like Primetech marks a crucial milestone in our strategy for long-term global growth. Through this, we are solidifying our distribution network in Asia, allowing us to offer our ground-breaking OOC solutions in this region and meet rapidly growing market demand.” said Dr Paul Brooks, CEO, CN Bio: “This agreement will allow us to provide specialized local support to our Japanese customers, and underpins our ongoing commitment to being an international provider of gold-standard OOC solutions, revolutionizing drug discovery on a global scale.”
About CN Bio cn-bio.com
CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated.
CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable effective therapeutics to be developed safely. Throughout the discovery and development process, the Company’s portfolio of products and services help save time and reduce costs.
Based in Cambridge (UK), CN Bio brings over a decade of experience and know-how to engineering single and multi-organ microphysiological systems (MPS). As a result, the Company’s ground-breaking benchtop PhysioMimix® OOC range can accurately mimic human physiology in the laboratory. Using advanced, predictive in vitro human organ models, these systems enable the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models also offer valuable insights into how drugs will perform in patients, greatly reducing risks in the clinic.
The power of PhysioMimix® technology has been recognized by the US FDA, resulting in the first co- publication between a drug regulator and an MPS provider and has been harnessed by 13 of the leading pharmaceutical companies. In 2023, CN Bio helped deliver a regulatory world first, when the Company supported Inipharm’s INI-822 successful filing to initiate clinical testing for the treatment of metabolic liver disease treatment.
To find out more about CN Bio and how the Company is pioneering faster, more accurate drug discovery, please visit: cn-bio.com
About Primetech Corporation www.primetech.co.jp
Primetech Corporation provides customers who are engaged in cutting-edge research in the field of life sciences with the most advanced equipment and systems in the world for more than 30 years, using the most advanced technology. We provide these instruments and systems with advanced expertise and technical capabilities, thereby contributing to the development of medical science.
